1-4 of 4
Holly Cranmer
Close
Sort by
Journal Articles

Network Meta-Analysis of Randomized Trials in Relapsed/Refractory Multiple Myeloma: Relative Efficacy for Patients Who Are Lenalidomide-Refractory

Efstathios Kastritis, Rebecca Harvey, Holly Cranmer, Martina Bianco, Elisabetta Fenu, Charles La Porte, Karthik Ramasamy
Journal: Blood
Blood (2023) 142 (Supplement 1): 7424.
https://doi.org/10.1182/blood-2023-180947
Published: 2023
Journal Articles

Delivering Systemic Anti-Cancer Treatment Via Another Route of Administration As an Option to Reduce Exposure to COVID-19 in Patients with Multiple Myeloma in the UK

Holly Cranmer, Tanja Podkonjak, Eugene Benson, Jonathon Dabora, Graham H Jackson, MD MA, MB BS, FRCP, FRCPath
Journal: Blood
Blood (2020) 136 (Supplement 1): 12–13.
https://doi.org/10.1182/blood-2020-142338
Published: 2020
Journal Articles

Serum Free Light Chain Assays in the Risk Stratification of Monoclonal Gammopathy of Undetermined Significance: Results from a Pharmacoeconomic Evaluation

Guy Pratt, MDFRCP FRCPath, Holly Cranmer, BSc, Christine Almond, MSC, MMath, Stephen Harding, PhD, Dale John Powner, PhD, Richard Geir Hughes, DPhil, Mark Cook, PhD MBChb
Journal: Blood
Blood (2015) 126 (23): 3258.
https://doi.org/10.1182/blood.V126.23.3258.3258
Published: 2015
Journal Articles

Serum Free Light Chain Assays in the Early Detection of Cast Nephropathy in Patients Presenting with Unexplained Acute Kidney Injury (AKI): Results from a Pharmacoeconomic Evaluation

Mark Cook, PhD FRCPath, Paul Cockwell, Christine Almond, Holly Cranmer, Stephen Harding, MDPhD, Richard Hughes, Chris Knight, Alexander Hirst
Journal: Blood
Blood (2014) 124 (21): 2612.
https://doi.org/10.1182/blood.V124.21.2612.2612
Published: 2014